Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831719 | 0.82 | IGF1R (0.65) | IGF1RINSRAURKA | |
| SCHEMBL14183645 | 0.81 | IGF1R (0.41) | IGF1RINSR | |
| SCHEMBL30353169 | 0.76 | IGF1R (0.57) | IGF1RINSRAURKAAURKB | |
| SCHEMBL30353136 | 0.76 | JAK2 (0.51) | IGF1RINSRAURKAGSK3BSRC | |
| SCHEMBL801533 | 0.76 | IGF1R (0.71) | IGF1RAURKAGSK3BSRCAURKB | |
| SCHEMBL801536 | 0.75 | IGF1R (0.70) | IGF1RAURKAGSK3BSRCAURKB | |
| SCHEMBL13609060 | 0.75 | IGF1R (0.61) | IGF1RINSRAURKAGSK3BSRC | |
| SCHEMBL12430701 | 0.75 | AURKA (0.63) | IGF1RAURKAGSK3BSRCAURKB | |
| SCHEMBL19990677 | 0.74 | AURKB (0.70) | IGF1RINSRAURKAGSK3BSRC | |
| SCHEMBL802154 | 0.74 | IGF1R (0.57) | IGF1RAURKAGSK3BSRCAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | claimed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | IGF1R 1146/4885INSR 1452/4885AURKA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.